AB 598
Alternative Names: AB-598Latest Information Update: 30 Dec 2025
At a glance
- Originator Arcus Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apyrase inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 22 Oct 2025 Safety and pharmacokinetics data from a phase-I clinical trials in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 05 Apr 2024 Pharmacodynamics data from a preclinical studies in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)